Drug intelligence / Profile preview

MIT-004

Development stage: Preclinical
Lead developer: MitoImmune Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

MIT-004 is an oral drug candidate being developed by MitoImmune Therapeutics for the treatment of Friedreich's Ataxia (FRDA). It is part of the company's mitochondrial and ferroptosis-modulating platform. While the specific molecular target has not been disclosed, the drug is designed to address mitochondrial dysfunction and oxidative stress, which are central to the pathogenesis of FRDA. As of early 2024, the program is in the discovery phase.

Beyond the preview

Go deeper on MIT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIT-004.

Explore the full profile